Silk Road Medical, Inc (SILK) Stock Competitors & Peer Comparison
See (SILK) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SILK | $27.49 | -0.04% | 1.1B | -18.96 | -$1.45 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $94.12 | +0.94% | 163.8B | 18.05 | $5.21 | +2.60% |
| ISRG | $404.70 | +1.25% | 143.2B | 42.02 | $9.62 | N/A |
| SYK | $332.71 | +5.25% | 127.6B | 24.85 | $13.39 | +1.04% |
| MDT | $80.98 | +0.57% | 103.6B | 14.64 | $5.53 | +3.53% |
| BSX | $44.23 | +0.07% | 65.6B | 14.24 | $3.10 | N/A |
| EW | $90.78 | +1.18% | 52.3B | 33.64 | $2.70 | N/A |
| RMD | $200.29 | +0.85% | 29.1B | 18.60 | $10.77 | +1.20% |
| DXCM | $70.14 | +2.17% | 27.1B | 30.10 | $2.33 | N/A |
Stock Comparison
SILK vs BSX-PA Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, SILK is priced at $27.49, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, SILK's ROE is -0.35%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, SILK is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check BSX-PA's competition here
SILK vs ABT Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ABT has a market cap of 163.8B. Regarding current trading prices, SILK is priced at $27.49, while ABT trades at $94.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ABT's P/E ratio is 18.05. In terms of profitability, SILK's ROE is -0.35%, compared to ABT's ROE of +0.12%. Regarding short-term risk, SILK is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check ABT's competition here
SILK vs ISRG Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ISRG has a market cap of 143.2B. Regarding current trading prices, SILK is priced at $27.49, while ISRG trades at $404.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ISRG's P/E ratio is 42.02. In terms of profitability, SILK's ROE is -0.35%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, SILK is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check ISRG's competition here
SILK vs SYK Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, SYK has a market cap of 127.6B. Regarding current trading prices, SILK is priced at $27.49, while SYK trades at $332.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas SYK's P/E ratio is 24.85. In terms of profitability, SILK's ROE is -0.35%, compared to SYK's ROE of +0.15%. Regarding short-term risk, SILK is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check SYK's competition here
SILK vs MDT Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, MDT has a market cap of 103.6B. Regarding current trading prices, SILK is priced at $27.49, while MDT trades at $80.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas MDT's P/E ratio is 14.64. In terms of profitability, SILK's ROE is -0.35%, compared to MDT's ROE of +0.10%. Regarding short-term risk, SILK is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check MDT's competition here
SILK vs BSX Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, BSX has a market cap of 65.6B. Regarding current trading prices, SILK is priced at $27.49, while BSX trades at $44.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas BSX's P/E ratio is 14.24. In terms of profitability, SILK's ROE is -0.35%, compared to BSX's ROE of +0.15%. Regarding short-term risk, SILK is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check BSX's competition here
SILK vs EW Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, EW has a market cap of 52.3B. Regarding current trading prices, SILK is priced at $27.49, while EW trades at $90.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas EW's P/E ratio is 33.64. In terms of profitability, SILK's ROE is -0.35%, compared to EW's ROE of +0.11%. Regarding short-term risk, SILK is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check EW's competition here
SILK vs RMD Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, RMD has a market cap of 29.1B. Regarding current trading prices, SILK is priced at $27.49, while RMD trades at $200.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas RMD's P/E ratio is 18.60. In terms of profitability, SILK's ROE is -0.35%, compared to RMD's ROE of +0.24%. Regarding short-term risk, SILK is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check RMD's competition here
SILK vs DXCM Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, DXCM has a market cap of 27.1B. Regarding current trading prices, SILK is priced at $27.49, while DXCM trades at $70.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas DXCM's P/E ratio is 30.10. In terms of profitability, SILK's ROE is -0.35%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, SILK is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check DXCM's competition here
SILK vs ZBH Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ZBH has a market cap of 18B. Regarding current trading prices, SILK is priced at $27.49, while ZBH trades at $93.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ZBH's P/E ratio is 26.23. In terms of profitability, SILK's ROE is -0.35%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, SILK is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check ZBH's competition here
SILK vs ABMD Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, SILK is priced at $27.49, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ABMD's P/E ratio is 65.36. In terms of profitability, SILK's ROE is -0.35%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, SILK is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check ABMD's competition here
SILK vs ALGN Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ALGN has a market cap of 12.8B. Regarding current trading prices, SILK is priced at $27.49, while ALGN trades at $178.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ALGN's P/E ratio is 16.27. In terms of profitability, SILK's ROE is -0.35%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, SILK is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check ALGN's competition here
SILK vs SNN Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, SILK is priced at $27.49, while SNN trades at $30.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas SNN's P/E ratio is 16.20. In terms of profitability, SILK's ROE is -0.35%, compared to SNN's ROE of +0.12%. Regarding short-term risk, SILK is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check SNN's competition here
SILK vs SWAV Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, SILK is priced at $27.49, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas SWAV's P/E ratio is 78.76. In terms of profitability, SILK's ROE is -0.35%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, SILK and SWAV have similar daily volatility (0.04).Check SWAV's competition here
SILK vs PEN Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, SILK is priced at $27.49, while PEN trades at $316.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas PEN's P/E ratio is 82.70. In terms of profitability, SILK's ROE is -0.35%, compared to PEN's ROE of +0.12%. Regarding short-term risk, SILK is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check PEN's competition here
SILK vs GMED Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, SILK is priced at $27.49, while GMED trades at $86.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas GMED's P/E ratio is 19.43. In terms of profitability, SILK's ROE is -0.35%, compared to GMED's ROE of +0.13%. Regarding short-term risk, SILK is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check GMED's competition here
SILK vs PODD Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, PODD has a market cap of 11B. Regarding current trading prices, SILK is priced at $27.49, while PODD trades at $158.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas PODD's P/E ratio is 29.41. In terms of profitability, SILK's ROE is -0.35%, compared to PODD's ROE of +0.21%. Regarding short-term risk, SILK is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check PODD's competition here
SILK vs MASI Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, SILK is priced at $27.49, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas MASI's P/E ratio is 44.43. In terms of profitability, SILK's ROE is -0.35%, compared to MASI's ROE of +0.09%. Regarding short-term risk, SILK is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for SILK.Check MASI's competition here
SILK vs BRKR Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, BRKR has a market cap of 9.3B. Regarding current trading prices, SILK is priced at $27.49, while BRKR trades at $60.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas BRKR's P/E ratio is 33.47. In terms of profitability, SILK's ROE is -0.35%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, SILK is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check BRKR's competition here
SILK vs GKOS Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, GKOS has a market cap of 8.5B. Regarding current trading prices, SILK is priced at $27.49, while GKOS trades at $144.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas GKOS's P/E ratio is -167.79. In terms of profitability, SILK's ROE is -0.35%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, SILK is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check GKOS's competition here
SILK vs BIO Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, BIO has a market cap of 8.1B. Regarding current trading prices, SILK is priced at $27.49, while BIO trades at $300.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas BIO's P/E ratio is 32.39. In terms of profitability, SILK's ROE is -0.35%, compared to BIO's ROE of +0.02%. Regarding short-term risk, SILK is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check BIO's competition here
SILK vs BIO-B Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, BIO-B has a market cap of 8B. Regarding current trading prices, SILK is priced at $27.49, while BIO-B trades at $317.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas BIO-B's P/E ratio is 94.17. In terms of profitability, SILK's ROE is -0.35%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, SILK is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for SILK.Check BIO-B's competition here
SILK vs NARI Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, SILK is priced at $27.49, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas NARI's P/E ratio is -59.24. In terms of profitability, SILK's ROE is -0.35%, compared to NARI's ROE of -0.00%. Regarding short-term risk, SILK is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for SILK.Check NARI's competition here
SILK vs LIVN Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, LIVN has a market cap of 4.6B. Regarding current trading prices, SILK is priced at $27.49, while LIVN trades at $83.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas LIVN's P/E ratio is 20.86. In terms of profitability, SILK's ROE is -0.35%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, SILK is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check LIVN's competition here
SILK vs IRTC Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, IRTC has a market cap of 3.9B. Regarding current trading prices, SILK is priced at $27.49, while IRTC trades at $118.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas IRTC's P/E ratio is -212.30. In terms of profitability, SILK's ROE is -0.35%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, SILK is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check IRTC's competition here
SILK vs AXNX Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, SILK is priced at $27.49, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas AXNX's P/E ratio is -709.80. In terms of profitability, SILK's ROE is -0.35%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, SILK is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for SILK.Check AXNX's competition here
SILK vs ITGR Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ITGR has a market cap of 3.2B. Regarding current trading prices, SILK is priced at $27.49, while ITGR trades at $93.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ITGR's P/E ratio is 14.90. In terms of profitability, SILK's ROE is -0.35%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, SILK is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check ITGR's competition here
SILK vs ESTA Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ESTA has a market cap of 2.6B. Regarding current trading prices, SILK is priced at $27.49, while ESTA trades at $88.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ESTA's P/E ratio is -61.37. In terms of profitability, SILK's ROE is -0.35%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, SILK is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check ESTA's competition here
SILK vs AXGN Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, AXGN has a market cap of 2.4B. Regarding current trading prices, SILK is priced at $27.49, while AXGN trades at $44.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas AXGN's P/E ratio is 118.24. In terms of profitability, SILK's ROE is -0.35%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, SILK is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check AXGN's competition here
SILK vs TMDX Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, TMDX has a market cap of 2.4B. Regarding current trading prices, SILK is priced at $27.49, while TMDX trades at $68.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas TMDX's P/E ratio is 27.93. In terms of profitability, SILK's ROE is -0.35%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, SILK is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check TMDX's competition here
SILK vs BFLY Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, BFLY has a market cap of 2.3B. Regarding current trading prices, SILK is priced at $27.49, while BFLY trades at $8.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas BFLY's P/E ratio is -36.87. In terms of profitability, SILK's ROE is -0.35%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, SILK is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check BFLY's competition here
SILK vs NUVA Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, SILK is priced at $27.49, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas NUVA's P/E ratio is 75.00. In terms of profitability, SILK's ROE is -0.35%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, SILK is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check NUVA's competition here
SILK vs UFPT Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, UFPT has a market cap of 2B. Regarding current trading prices, SILK is priced at $27.49, while UFPT trades at $259.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas UFPT's P/E ratio is 26.48. In terms of profitability, SILK's ROE is -0.35%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, SILK is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check UFPT's competition here
SILK vs NVCR Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, SILK is priced at $27.49, while NVCR trades at $15.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas NVCR's P/E ratio is -10.08. In terms of profitability, SILK's ROE is -0.35%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, SILK is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check NVCR's competition here
SILK vs IART Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, IART has a market cap of 1.5B. Regarding current trading prices, SILK is priced at $27.49, while IART trades at $18.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas IART's P/E ratio is 7.95. In terms of profitability, SILK's ROE is -0.35%, compared to IART's ROE of -0.48%. Regarding short-term risk, SILK is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check IART's competition here
SILK vs ATEC Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, SILK is priced at $27.49, while ATEC trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ATEC's P/E ratio is -84.55. In terms of profitability, SILK's ROE is -0.35%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, SILK is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check ATEC's competition here
SILK vs AHCO Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, SILK is priced at $27.49, while AHCO trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas AHCO's P/E ratio is 23.39. In terms of profitability, SILK's ROE is -0.35%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, SILK is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check AHCO's competition here
SILK vs INSP Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, INSP has a market cap of 1.3B. Regarding current trading prices, SILK is priced at $27.49, while INSP trades at $45.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas INSP's P/E ratio is 17.69. In terms of profitability, SILK's ROE is -0.35%, compared to INSP's ROE of +0.18%. Regarding short-term risk, SILK is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check INSP's competition here
SILK vs HSKA Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, SILK is priced at $27.49, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas HSKA's P/E ratio is -62.49. In terms of profitability, SILK's ROE is -0.35%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, SILK is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for SILK.Check HSKA's competition here
SILK vs ENOV Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ENOV has a market cap of 1.3B. Regarding current trading prices, SILK is priced at $27.49, while ENOV trades at $22.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ENOV's P/E ratio is 6.71. In terms of profitability, SILK's ROE is -0.35%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, SILK is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check ENOV's competition here
SILK vs PRCT Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, SILK is priced at $27.49, while PRCT trades at $22.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas PRCT's P/E ratio is -12.40. In terms of profitability, SILK's ROE is -0.35%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, SILK is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check PRCT's competition here
SILK vs IRMD Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, SILK is priced at $27.49, while IRMD trades at $93.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas IRMD's P/E ratio is 47.22. In terms of profitability, SILK's ROE is -0.35%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, SILK is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check IRMD's competition here
SILK vs AVNS Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, SILK is priced at $27.49, while AVNS trades at $24.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas AVNS's P/E ratio is 27.71. In terms of profitability, SILK's ROE is -0.35%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, SILK is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check AVNS's competition here
SILK vs LMRI Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, LMRI has a market cap of 1.2B. Regarding current trading prices, SILK is priced at $27.49, while LMRI trades at $12.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas LMRI's P/E ratio is -23.54. In terms of profitability, SILK's ROE is -0.35%, compared to LMRI's ROE of -0.14%. Regarding short-term risk, SILK is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check LMRI's competition here
SILK vs AORT Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, SILK is priced at $27.49, while AORT trades at $23.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas AORT's P/E ratio is 36.29. In terms of profitability, SILK's ROE is -0.35%, compared to AORT's ROE of +0.03%. Regarding short-term risk, SILK is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check AORT's competition here
SILK vs TNDM Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, SILK is priced at $27.49, while TNDM trades at $16.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas TNDM's P/E ratio is -14.76. In terms of profitability, SILK's ROE is -0.35%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, SILK is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check TNDM's competition here
SILK vs FNA Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, SILK is priced at $27.49, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas FNA's P/E ratio is -19.83. In terms of profitability, SILK's ROE is -0.35%, compared to FNA's ROE of -0.35%. Regarding short-term risk, SILK is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check FNA's competition here
SILK vs CNMD Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, SILK is priced at $27.49, while CNMD trades at $35.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas CNMD's P/E ratio is 7.90. In terms of profitability, SILK's ROE is -0.35%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, SILK is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check CNMD's competition here
SILK vs CSII Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, SILK is priced at $27.49, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas CSII's P/E ratio is -20.83. In terms of profitability, SILK's ROE is -0.35%, compared to CSII's ROE of -0.14%. Regarding short-term risk, SILK is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check CSII's competition here
SILK vs INMD Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, INMD has a market cap of 840.9M. Regarding current trading prices, SILK is priced at $27.49, while INMD trades at $14.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas INMD's P/E ratio is 9.38. In terms of profitability, SILK's ROE is -0.35%, compared to INMD's ROE of +0.13%. Regarding short-term risk, SILK is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check INMD's competition here
SILK vs SIBN Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, SIBN has a market cap of 768.6M. Regarding current trading prices, SILK is priced at $27.49, while SIBN trades at $17.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas SIBN's P/E ratio is -44.44. In terms of profitability, SILK's ROE is -0.35%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, SILK is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check SIBN's competition here
SILK vs CBLL Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, CBLL has a market cap of 758.1M. Regarding current trading prices, SILK is priced at $27.49, while CBLL trades at $19.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas CBLL's P/E ratio is -12.26. In terms of profitability, SILK's ROE is -0.35%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, SILK is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check CBLL's competition here
SILK vs CRY Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, SILK is priced at $27.49, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas CRY's P/E ratio is 425.71. In terms of profitability, SILK's ROE is -0.35%, compared to CRY's ROE of +0.03%. Regarding short-term risk, SILK is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check CRY's competition here
SILK vs TCMD Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, TCMD has a market cap of 683M. Regarding current trading prices, SILK is priced at $27.49, while TCMD trades at $30.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas TCMD's P/E ratio is 34.41. In terms of profitability, SILK's ROE is -0.35%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, SILK is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check TCMD's competition here
SILK vs SSII Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, SSII has a market cap of 668.4M. Regarding current trading prices, SILK is priced at $27.49, while SSII trades at $3.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas SSII's P/E ratio is -65.15. In terms of profitability, SILK's ROE is -0.35%, compared to SSII's ROE of -0.23%. Regarding short-term risk, SILK is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check SSII's competition here
SILK vs BVS Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, BVS has a market cap of 660.5M. Regarding current trading prices, SILK is priced at $27.49, while BVS trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas BVS's P/E ratio is 13.00. In terms of profitability, SILK's ROE is -0.35%, compared to BVS's ROE of +0.16%. Regarding short-term risk, SILK is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check BVS's competition here
SILK vs SRDX Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, SILK is priced at $27.49, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas SRDX's P/E ratio is -34.66. In terms of profitability, SILK's ROE is -0.35%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, SILK is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for SILK.Check SRDX's competition here
SILK vs CERS Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, CERS has a market cap of 585.1M. Regarding current trading prices, SILK is priced at $27.49, while CERS trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas CERS's P/E ratio is -58.28. In terms of profitability, SILK's ROE is -0.35%, compared to CERS's ROE of -0.15%. Regarding short-term risk, SILK is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check CERS's competition here
SILK vs APEN Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, SILK is priced at $27.49, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas APEN's P/E ratio is -9.43. In terms of profitability, SILK's ROE is -0.35%, compared to APEN's ROE of -0.85%. Regarding short-term risk, SILK is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check APEN's competition here
SILK vs CTKB Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, CTKB has a market cap of 578.6M. Regarding current trading prices, SILK is priced at $27.49, while CTKB trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas CTKB's P/E ratio is -34.46. In terms of profitability, SILK's ROE is -0.35%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, SILK is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check CTKB's competition here
SILK vs BWAY Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, BWAY has a market cap of 567.9M. Regarding current trading prices, SILK is priced at $27.49, while BWAY trades at $14.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas BWAY's P/E ratio is 36.78. In terms of profitability, SILK's ROE is -0.35%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, SILK is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check BWAY's competition here
SILK vs NPCE Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, NPCE has a market cap of 560.2M. Regarding current trading prices, SILK is priced at $27.49, while NPCE trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas NPCE's P/E ratio is -28.33. In terms of profitability, SILK's ROE is -0.35%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, SILK is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check NPCE's competition here
SILK vs CLPT Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, CLPT has a market cap of 554.2M. Regarding current trading prices, SILK is priced at $27.49, while CLPT trades at $18.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas CLPT's P/E ratio is -18.30. In terms of profitability, SILK's ROE is -0.35%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, SILK is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check CLPT's competition here
SILK vs ZIMV Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, SILK is priced at $27.49, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, SILK's ROE is -0.35%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, SILK is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for SILK.Check ZIMV's competition here
SILK vs KIDS Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, KIDS has a market cap of 521.4M. Regarding current trading prices, SILK is priced at $27.49, while KIDS trades at $20.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas KIDS's P/E ratio is -19.71. In terms of profitability, SILK's ROE is -0.35%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, SILK is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check KIDS's competition here
SILK vs PACB Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, PACB has a market cap of 512.5M. Regarding current trading prices, SILK is priced at $27.49, while PACB trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas PACB's P/E ratio is -3.37. In terms of profitability, SILK's ROE is -0.35%, compared to PACB's ROE of -4.88%. Regarding short-term risk, SILK is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check PACB's competition here
SILK vs DCTH Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, DCTH has a market cap of 446.7M. Regarding current trading prices, SILK is priced at $27.49, while DCTH trades at $12.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas DCTH's P/E ratio is 1294.00. In terms of profitability, SILK's ROE is -0.35%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, SILK is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check DCTH's competition here
SILK vs VREX Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, VREX has a market cap of 432.4M. Regarding current trading prices, SILK is priced at $27.49, while VREX trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas VREX's P/E ratio is 10.81. In terms of profitability, SILK's ROE is -0.35%, compared to VREX's ROE of -0.18%. Regarding short-term risk, SILK is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check VREX's competition here
SILK vs OFIX Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, OFIX has a market cap of 395.3M. Regarding current trading prices, SILK is priced at $27.49, while OFIX trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas OFIX's P/E ratio is -39.84. In terms of profitability, SILK's ROE is -0.35%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, SILK is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check OFIX's competition here
SILK vs AVR Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, AVR has a market cap of 356.5M. Regarding current trading prices, SILK is priced at $27.49, while AVR trades at $9.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas AVR's P/E ratio is -4.35. In terms of profitability, SILK's ROE is -0.35%, compared to AVR's ROE of -1.24%. Regarding short-term risk, SILK is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check AVR's competition here
SILK vs ELMD Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ELMD has a market cap of 341.3M. Regarding current trading prices, SILK is priced at $27.49, while ELMD trades at $41.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ELMD's P/E ratio is 35.23. In terms of profitability, SILK's ROE is -0.35%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, SILK is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check ELMD's competition here
SILK vs SMLR Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, SILK is priced at $27.49, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas SMLR's P/E ratio is 3.92. In terms of profitability, SILK's ROE is -0.35%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, SILK is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for SILK.Check SMLR's competition here
SILK vs SGHT Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, SGHT has a market cap of 309.6M. Regarding current trading prices, SILK is priced at $27.49, while SGHT trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas SGHT's P/E ratio is -9.03. In terms of profitability, SILK's ROE is -0.35%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, SILK is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check SGHT's competition here
SILK vs TMCI Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, TMCI has a market cap of 289.3M. Regarding current trading prices, SILK is priced at $27.49, while TMCI trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas TMCI's P/E ratio is -4.74. In terms of profitability, SILK's ROE is -0.35%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, SILK is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check TMCI's competition here
SILK vs PMI Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, PMI has a market cap of 250.7M. Regarding current trading prices, SILK is priced at $27.49, while PMI trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas PMI's P/E ratio is -0.13. In terms of profitability, SILK's ROE is -0.35%, compared to PMI's ROE of +4.99%. Regarding short-term risk, SILK is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check PMI's competition here
SILK vs MGRM Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, SILK is priced at $27.49, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas MGRM's P/E ratio is -11.11. In terms of profitability, SILK's ROE is -0.35%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, SILK is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for SILK.Check MGRM's competition here
SILK vs SENS Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, SENS has a market cap of 239.1M. Regarding current trading prices, SILK is priced at $27.49, while SENS trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas SENS's P/E ratio is -2.86. In terms of profitability, SILK's ROE is -0.35%, compared to SENS's ROE of -1.30%. Regarding short-term risk, SILK is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check SENS's competition here
SILK vs CATX Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, CATX has a market cap of 231.8M. Regarding current trading prices, SILK is priced at $27.49, while CATX trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas CATX's P/E ratio is -2.13. In terms of profitability, SILK's ROE is -0.35%, compared to CATX's ROE of -0.42%. Regarding short-term risk, SILK is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check CATX's competition here
SILK vs NVRO Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, SILK is priced at $27.49, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas NVRO's P/E ratio is -1.91. In terms of profitability, SILK's ROE is -0.35%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, SILK is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check NVRO's competition here
SILK vs RXST Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, RXST has a market cap of 221.9M. Regarding current trading prices, SILK is priced at $27.49, while RXST trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas RXST's P/E ratio is -7.44. In terms of profitability, SILK's ROE is -0.35%, compared to RXST's ROE of -0.17%. Regarding short-term risk, SILK is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check RXST's competition here
SILK vs EYES Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, SILK is priced at $27.49, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas EYES's P/E ratio is N/A. In terms of profitability, SILK's ROE is -0.35%, compared to EYES's ROE of -2.64%. Regarding short-term risk, SILK is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check EYES's competition here
SILK vs QTRX Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, QTRX has a market cap of 203.5M. Regarding current trading prices, SILK is priced at $27.49, while QTRX trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas QTRX's P/E ratio is -2.70. In terms of profitability, SILK's ROE is -0.35%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, SILK is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check QTRX's competition here
SILK vs ANIK Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ANIK has a market cap of 200.9M. Regarding current trading prices, SILK is priced at $27.49, while ANIK trades at $15.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ANIK's P/E ratio is 30.82. In terms of profitability, SILK's ROE is -0.35%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, SILK is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check ANIK's competition here
SILK vs PROF Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, PROF has a market cap of 196.7M. Regarding current trading prices, SILK is priced at $27.49, while PROF trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas PROF's P/E ratio is -5.24. In terms of profitability, SILK's ROE is -0.35%, compared to PROF's ROE of -0.70%. Regarding short-term risk, SILK is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check PROF's competition here
SILK vs FOCL Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, FOCL has a market cap of 191.2M. Regarding current trading prices, SILK is priced at $27.49, while FOCL trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas FOCL's P/E ratio is -10.31. In terms of profitability, SILK's ROE is -0.35%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, SILK is less volatile compared to FOCL. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check FOCL's competition here
SILK vs BSGM Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, SILK is priced at $27.49, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas BSGM's P/E ratio is -5.81. In terms of profitability, SILK's ROE is -0.35%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, SILK is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check BSGM's competition here
SILK vs INGN Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, INGN has a market cap of 187.9M. Regarding current trading prices, SILK is priced at $27.49, while INGN trades at $6.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas INGN's P/E ratio is -7.63. In terms of profitability, SILK's ROE is -0.35%, compared to INGN's ROE of -0.13%. Regarding short-term risk, SILK is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check INGN's competition here
SILK vs TLSI Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, TLSI has a market cap of 179.3M. Regarding current trading prices, SILK is priced at $27.49, while TLSI trades at $4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas TLSI's P/E ratio is -2.82. In terms of profitability, SILK's ROE is -0.35%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, SILK is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check TLSI's competition here
SILK vs MDGS Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, SILK is priced at $27.49, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas MDGS's P/E ratio is -0.27. In terms of profitability, SILK's ROE is -0.35%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, SILK is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check MDGS's competition here
SILK vs QIPT Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, SILK is priced at $27.49, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas QIPT's P/E ratio is -15.87. In terms of profitability, SILK's ROE is -0.35%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, SILK is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for SILK.Check QIPT's competition here
SILK vs CVRX Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, CVRX has a market cap of 155.5M. Regarding current trading prices, SILK is priced at $27.49, while CVRX trades at $5.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas CVRX's P/E ratio is -2.90. In terms of profitability, SILK's ROE is -0.35%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, SILK is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check CVRX's competition here
SILK vs QTI Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, QTI has a market cap of 110.4M. Regarding current trading prices, SILK is priced at $27.49, while QTI trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas QTI's P/E ratio is -5.99. In terms of profitability, SILK's ROE is -0.35%, compared to QTI's ROE of -63.31%. Regarding short-term risk, SILK is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check QTI's competition here
SILK vs LUCD Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, LUCD has a market cap of 108.4M. Regarding current trading prices, SILK is priced at $27.49, while LUCD trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas LUCD's P/E ratio is -2.86. In terms of profitability, SILK's ROE is -0.35%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, SILK is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check LUCD's competition here
SILK vs ICAD Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, SILK is priced at $27.49, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ICAD's P/E ratio is -20.37. In terms of profitability, SILK's ROE is -0.35%, compared to ICAD's ROE of -0.06%. Regarding short-term risk, SILK is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for SILK.Check ICAD's competition here
SILK vs HSDT Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, HSDT has a market cap of 101M. Regarding current trading prices, SILK is priced at $27.49, while HSDT trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas HSDT's P/E ratio is -0.02. In terms of profitability, SILK's ROE is -0.35%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, SILK is less volatile compared to HSDT. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check HSDT's competition here
SILK vs OWLT Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, OWLT has a market cap of 99.3M. Regarding current trading prices, SILK is priced at $27.49, while OWLT trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas OWLT's P/E ratio is -39.21. In terms of profitability, SILK's ROE is -0.35%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, SILK is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check OWLT's competition here
SILK vs RCEL Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, RCEL has a market cap of 98.6M. Regarding current trading prices, SILK is priced at $27.49, while RCEL trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas RCEL's P/E ratio is -2.53. In terms of profitability, SILK's ROE is -0.35%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, SILK is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check RCEL's competition here
SILK vs HJLI Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, SILK is priced at $27.49, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas HJLI's P/E ratio is N/A. In terms of profitability, SILK's ROE is -0.35%, compared to HJLI's ROE of -0.66%. Regarding short-term risk, SILK is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check HJLI's competition here
SILK vs ASXC Comparison June 2026
SILK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SILK stands at 1.1B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, SILK is priced at $27.49, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SILK currently has a P/E ratio of -18.96, whereas ASXC's P/E ratio is -1.12. In terms of profitability, SILK's ROE is -0.35%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, SILK is less volatile compared to ASXC. This indicates potentially lower risk in terms of short-term price fluctuations for SILK.Check ASXC's competition here